$ATRA
Atara Biotherapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023018820 Filed on May 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q4
Revenue $957.0K $1.226M $221.0K
YoY Change -98.14% -83.24% -97.07%
Cost Of Revenue $2.895M $216.0K
YoY Change
Gross Profit -$1.938M $1.010M
YoY Change
Gross Profit Margin -202.51% 82.38%
Selling, General & Admin $13.34M $13.83M $13.01M
YoY Change -29.12% -32.78% -40.39%
% of Gross Profit 1369.01%
Research & Development $56.14M $62.16M $62.68M
YoY Change -13.49% -17.08% -20.79%
% of Gross Profit 6154.06%
Depreciation & Amortization $900.0K $900.0K $1.255M
YoY Change -37.41% -43.43% -49.56%
% of Gross Profit 89.11%
Operating Expenses $72.37M $76.24M $75.69M
YoY Change -13.55% -20.19% -25.03%
Operating Profit -$71.41M -$75.02M
YoY Change 122.25% -14.96%
Interest Expense $1.378M $1.336M $969.0K
YoY Change 281.72% 1061.74% 1053.57%
% of Operating Profit
Other Income/Expense, Net -$10.00K -$197.0K
YoY Change -102.77% -271.3%
Pretax Income -$71.11M -$74.75M -$74.57M
YoY Change -485.07% -15.16% -20.09%
Income Tax $1.000K $22.00K $2.000K
% Of Pretax Income
Net Earnings -$71.11M -$74.77M -$74.57M
YoY Change -485.08% -15.13% -20.11%
Net Earnings / Revenue -7430.3% -6098.78% -33742.99%
Basic Earnings Per Share -$0.68 -$0.72
Diluted Earnings Per Share -$0.68 -$0.72 -$0.72
COMMON SHARES
Basic Shares Outstanding 97.97M 95.93M 94.88M
Diluted Shares Outstanding 105.1M 104.0M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $153.6M $205.4M $242.8M
YoY Change -53.63% -31.94% -34.56%
Cash & Equivalents $45.90M $48.74M $92.94M
Short-Term Investments $107.7M $156.7M $149.9M
Other Short-Term Assets $10.16M $12.89M $10.31M
YoY Change -32.4% 8.25% -17.98%
Inventory $7.861M $5.340M $1.586M
Prepaid Expenses
Receivables $507.0K $397.0K $40.22M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $172.3M $224.2M $295.1M
YoY Change -50.34% -28.69% -23.28%
LONG-TERM ASSETS
Property, Plant & Equipment $5.349M $5.852M $74.32M
YoY Change -35.77% -35.76% 38.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.575M $6.906M $7.018M
YoY Change -9.02% -87.41% 196.49%
Total Long-Term Assets $74.12M $77.90M $81.34M
YoY Change -16.85% -6.02% -2.59%
TOTAL ASSETS
Total Short-Term Assets $172.3M $224.2M $295.1M
Total Long-Term Assets $74.12M $77.90M $81.34M
Total Assets $246.4M $302.1M $376.4M
YoY Change -43.49% -23.96% -19.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.138M $5.068M $6.871M
YoY Change -67.67% -57.57% -60.44%
Accrued Expenses $10.65M $6.764M $63.21M
YoY Change -66.14% -77.73% 960.59%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $859.0K $832.0K $834.0K
YoY Change 2.38% 387.72%
Total Short-Term Liabilities $74.55M $67.88M $78.92M
YoY Change 13.49% -33.17% -25.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $3.643M
YoY Change
Other Long-Term Liabilities $5.023M $5.177M $167.2M
YoY Change -10.72% 740.42% 11040.64%
Total Long-Term Liabilities $5.023M $5.177M $170.9M
YoY Change -10.72% 740.42% 11283.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $74.55M $67.88M $78.92M
Total Long-Term Liabilities $5.023M $5.177M $170.9M
Total Liabilities $239.0M $237.1M $249.8M
YoY Change 33.78% 132.07% 32.5%
SHAREHOLDERS EQUITY
Retained Earnings -$1.839B -$1.768B -$1.693B
YoY Change 19.85% 15.59%
Common Stock $1.847B $1.834B $1.822B
YoY Change 2.94% 4.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.454M $64.96M $126.6M
YoY Change
Total Liabilities & Shareholders Equity $246.4M $302.1M $376.4M
YoY Change -43.49% -23.96% -19.59%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income -$71.11M -$74.77M -$74.57M
YoY Change -485.08% -15.13% -20.11%
Depreciation, Depletion And Amortization $900.0K $900.0K $1.255M
YoY Change -37.41% -43.43% -49.56%
Cash From Operating Activities -$52.80M -$38.43M -$56.88M
YoY Change -17.46% -54.54% 65.98%
INVESTING ACTIVITIES
Capital Expenditures $499.0K $399.0K $37.00K
YoY Change -135.17% -84.68% -101.5%
Acquisitions
YoY Change
Other Investing Activities $49.98M -$5.608M $51.25M
YoY Change 50.34% -108.93% -334.49%
Cash From Investing Activities $49.48M -$6.007M $51.22M
YoY Change 55.48% -109.98% -310.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 471.0K 235.0K 32.29M
YoY Change -59.29% -98.82% -37.26%
NET CHANGE
Cash From Operating Activities -52.80M -38.43M -56.88M
Cash From Investing Activities 49.48M -6.007M 51.22M
Cash From Financing Activities 471.0K 235.0K 32.29M
Net Change In Cash -2.843M -44.20M 26.63M
YoY Change -90.82% 890.39% -473.73%
FREE CASH FLOW
Cash From Operating Activities -$52.80M -$38.43M -$56.88M
Capital Expenditures $499.0K $399.0K $37.00K
Free Cash Flow -$53.29M -$38.83M -$56.92M
YoY Change -14.79% -55.44% 78.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001604464
CY2023Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-08-01
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36548
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
ATARA BIOTHERAPEUTICS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-0920988
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2380 Conejo Spectrum Street
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Thousand Oaks
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91320
CY2023Q1 dei City Area Code
CityAreaCode
805
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
623-4211
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
ATRA
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
97972246
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48741000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92942000
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
156666000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
149877000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2022Q2 atra Supply Agreement Maximum Extension Term
SupplyAgreementMaximumExtensionTerm
P10Y
CY2023Q1 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
397000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
40221000
CY2023Q1 us-gaap Inventory Net
InventoryNet
5340000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1586000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
12892000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
10308000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
224182000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
295080000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5852000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6300000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
65143000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
68022000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6906000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7018000
CY2023Q1 us-gaap Assets
Assets
302083000
CY2022Q4 us-gaap Assets
Assets
376420000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5068000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6871000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8913000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17659000
CY2023Q1 atra Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
23766000
CY2022Q4 atra Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
24992000
CY2023Q1 us-gaap Deferred Income Current
DeferredIncomeCurrent
9924000
CY2022Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
8000000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
20205000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21394000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
67876000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
78916000
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
78041000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
77000000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
54918000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
58064000
CY2023Q1 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
31111000
CY2022Q4 atra Liability Related To The Sale Of Future Royalties Long Term
LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm
30236000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5177000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5564000
CY2023Q1 us-gaap Liabilities
Liabilities
237123000
CY2022Q4 us-gaap Liabilities
Liabilities
249780000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
96538000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
96538000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
95927000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
95927000
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
10000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1833982000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1821721000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1237000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2067000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1767795000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1693024000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
64960000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
126640000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
302083000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
376420000
CY2023Q1 atra Commercialization Revenue
CommercializationRevenue
884000
CY2022Q1 atra Commercialization Revenue
CommercializationRevenue
0
CY2023Q1 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
342000
CY2022Q1 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
7314000
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1226000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7314000
CY2023Q1 atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
216000
CY2022Q1 atra Cost Of Commercialization Revenue
CostOfCommercializationRevenue
0
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62156000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
74963000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13872000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20571000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
76244000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
95534000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-75018000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-88220000
CY2023Q1 us-gaap Interest Income Operating
InterestIncomeOperating
1802000
CY2022Q1 us-gaap Interest Income Operating
InterestIncomeOperating
228000
CY2023Q1 us-gaap Interest Expense
InterestExpense
1336000
CY2022Q1 us-gaap Interest Expense
InterestExpense
4000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-197000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-109000
CY2023Q1 atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
269000
CY2022Q1 atra Total Other Income Expense Net
TotalOtherIncomeExpenseNet
115000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-74749000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-88105000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
22000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-74771000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-88105000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
830000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1524000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-73941000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-89629000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103969000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
103969000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
100726000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100726000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
126640000
CY2023Q1 atra Issuance Of Common Stock Net Of Commissions And Offering Costs Value
IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
590000
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
93000
CY2023Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
0
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11764000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-74771000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
830000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
64960000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
279614000
CY2022Q1 atra Issuance Of Common Stock Net Of Commissions And Offering Costs Value
IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue
20516000
CY2022Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
616000
CY2022Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
96000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14335000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-88105000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1524000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
224316000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-74771000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-88105000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
11764000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
14335000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1214000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1591000
CY2023Q1 us-gaap Accretion Expense
AccretionExpense
1204000
CY2022Q1 us-gaap Accretion Expense
AccretionExpense
0
CY2023Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
351000
CY2022Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-498000
CY2023Q1 atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
2879000
CY2022Q1 atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
627000
CY2023Q1 atra Other Non Cash Items Net
OtherNonCashItemsNet
80000
CY2022Q1 atra Other Non Cash Items Net
OtherNonCashItemsNet
7000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-39824000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-318000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3754000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2584000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-609000
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
156000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-51000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1886000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4588000
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-8746000
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-8769000
CY2023Q1 atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-1226000
CY2022Q1 atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
539000
CY2023Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-609000
CY2022Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-570000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2965000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-525000
CY2023Q1 atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4174000
CY2022Q1 atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-645000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-102000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
98000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38429000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-84529000
CY2023Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
67903000
CY2022Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
26427000
CY2023Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
62295000
CY2022Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
89247000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
399000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2605000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6007000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
60215000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
640000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20539000
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
CY2022Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
96000
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
93000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
616000
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
312000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
64000
CY2023Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-104000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
235000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19851000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-44201000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4463000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93088000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
107478000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48887000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103015000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
194000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1188000
CY2023Q1 atra Non Cash Investing And Financing Activities Accrued Costs Related To At The Market Facility
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility
73000
CY2022Q1 atra Non Cash Investing And Financing Activities Accrued Costs Related To At The Market Facility
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility
23000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
112000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
5000
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
14000
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
100000000
CY2023Q1 atra Common Stock Reserved For Future Issuance Value
CommonStockReservedForFutureIssuanceValue
55200000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to revenue recognition, accrued research and development expenses, stock-based compensation expense, income taxes and the liability related to the sale of future revenues. Actual results could differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24479689
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19010181
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
187841000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
187032000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
202323000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
201359000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
18370000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
17942000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
36746000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
35643000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
206211000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
204974000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
239069000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
237002000
CY2023Q1 us-gaap Interest Receivable
InterestReceivable
700000
CY2022Q4 us-gaap Interest Receivable
InterestReceivable
800000
CY2023Q1 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2022Q1 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48741000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92942000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48887000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93088000
CY2022Q4 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2023Q1 atra Minimum Commitments Expense
MinimumCommitmentsExpense
9500000
CY2022Q1 atra Minimum Commitments Expense
MinimumCommitmentsExpense
0
CY2023Q1 atra Research And Development Costs Related To Minimum Purchase Commitments
ResearchAndDevelopmentCostsRelatedToMinimumPurchaseCommitments
8000000.0
CY2022 atra Research And Development Costs Related To Minimum Purchase Commitments
ResearchAndDevelopmentCostsRelatedToMinimumPurchaseCommitments
9200000
CY2023Q1 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2022Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2022Q4 us-gaap Prepaid Royalties
PrepaidRoyalties
30236000
CY2023Q1 us-gaap Accretion Expense
AccretionExpense
1204000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
20000
CY2023Q1 us-gaap Payments For Royalties
PaymentsForRoyalties
0
CY2023Q1 us-gaap Prepaid Royalties
PrepaidRoyalties
31460000
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
349000
CY2023Q1 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
31111000
CY2022Q3 atra Reduction In Current Workforce Percentage
ReductionInCurrentWorkforcePercentage
0.20
CY2022Q3 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
6000000.0
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
45000
CY2022Q1 us-gaap Restructuring Charges
RestructuringCharges
0
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
1545000
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
45000
CY2023Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
852000
CY2023Q1 us-gaap Restructuring Reserve
RestructuringReserve
738000
CY2023Q1 atra Contractual Obligations Due To Licensors
ContractualObligationsDueToLicensors
0
CY2022Q4 atra Contractual Obligations Due To Licensors
ContractualObligationsDueToLicensors
0
CY2023Q1 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2022Q4 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 atra Common Stock Value Remained Available To Be Sold
CommonStockValueRemainedAvailableToBeSold
55200000
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
29213106
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11764000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14335000
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
1324000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1214000
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
4016000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
372000
CY2023Q1 us-gaap Inventory Net
InventoryNet
5340000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1586000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19113000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18722000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13261000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12422000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5852000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6300000
CY2023Q1 us-gaap Depreciation
Depreciation
900000
CY2022Q1 us-gaap Depreciation
Depreciation
1500000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6764000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7435000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11778000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12806000
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
832000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
834000
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
349000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
482000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
319000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
20205000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21394000

Files In Submission

Name View Source Status
atra-20230331_def.xml Edgar Link unprocessable
atra-20230331_pre.xml Edgar Link unprocessable
0000950170-23-018820-index-headers.html Edgar Link pending
0000950170-23-018820-index.html Edgar Link pending
0000950170-23-018820.txt Edgar Link pending
0000950170-23-018820-xbrl.zip Edgar Link pending
atra-20230331.htm Edgar Link pending
atra-20230331.xsd Edgar Link pending
atra-ex10_1.htm Edgar Link pending
atra-ex31_1.htm Edgar Link pending
atra-ex31_2.htm Edgar Link pending
atra-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
atra-20230331_cal.xml Edgar Link unprocessable
atra-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
atra-20230331_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending